Pharmacology News and Research

Latest Pharmacology News and Research

Researchers identify new type of potential anticancer drug

Researchers at Emory University School of Medicine have identified a new type of potential anticancer drug. The compound, named FOBISIN, targets 14-3-3 proteins, important for the runaway growth of cancer cells.

13 Sep 2011

Frontage, Spaulding Clinical enter strategic partnership

Frontage Laboratories, Inc., a global full-service Clinical Research Organization with facilities in the US and China, and Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical Pharmacology Unit, ECG Core Lab, and Medical Device Manufacturer have entered into a strategic partnership agreement.

12 Sep 2011

Febrile seizures in children may be linked to respiratory alkalosis

New research shows that febrile seizures in children may be linked to respiratory alkalosis, indicated by elevated blood pH and low carbon dioxide levels caused by hyperventilation, and independent of the underlying infection severity.

12 Sep 2011

Pharmacologists study first drug-resistant strain of pneumonia to enter Texas

A team of researchers from the University of Houston (UH) and St. Luke's Episcopal Hospital (SLEH) are working to develop improved screening methods to detect a potentially lethal, drug-resistant superbug that has made its way to Texas.

9 Sep 2011

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways.

8 Sep 2011

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.

7 Sep 2011

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

International researchers to assess role of pre-clinical animal models in drug discovery

The New York Academy of Sciences and the Global Medical Excellence Cluster (GMEC), in collaboration with Imperial College London and King's College London, will host a two-day scientific conference, "Animal Models and Their Value in Predicting Drug Efficacy and Toxicity," that will provide a forum to critically examine the role of pre-clinical animal models in drug discovery.

7 Sep 2011

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

Study describes new class of anti-diabetic compound that targets unique molecular switch

In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.

5 Sep 2011

Resveratrol helps prevent metabolic syndrome in offspring

Researchers in the Faculty of Medicine & Dentistry at the University of Alberta have discovered that resveratrol, a powerful antioxidant found in common foods, prevents a syndrome in some offspring that could lead to later health issues such as diabetes.

3 Sep 2011

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

University of Florida researchers have modified a toxic chemical produced by tiny marine microbes and successfully deployed it against laboratory models of colon cancer.

2 Sep 2011

Discovery in rare disease may shed light on common causes of blindness

In a rare eye disease, the retina degenerates because light-receiving cells fail to regenerate, research led by a student at Case Western Reserve University School of Medicine shows.

2 Sep 2011

UC Davis computer model can test effects of anti-arrhythmia medications

UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

2 Sep 2011

Insight into molecular basis of Enhanced S-Cone Syndrome

A new research report published in The FASEB Journal will help ophthalmologists and scientists better understand a rare genetic disease that causes increased susceptibility to blue light, night blindness, and decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome.

2 Sep 2011

Creighton pharmacology professor receives AAF's Early Excellence Award

Yaping Tu, Ph.D., associate professor of pharmacology at Creighton University School of Medicine, has received a $450,000 Early Excellence Award from the American Asthma Foundation.

31 Aug 2011

Bristol-Myers Squibb selects ICON as preferred provider for early phase clinical development

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been chosen by Bristol-Myers Squibb Company as a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

30 Aug 2011

Harmful effects of tobacco smoke on atherosclerosis are greater in women than in men

The harmful effects of tobacco smoke on atherosclerosis, one of the driving forces of cardiovascular disease, are greater in women than in men.

29 Aug 2011

Elsevier, Pharmaron sign multi-year contract for Reaxys

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that Pharmaron, a premier drug R&D service provider for the pharmaceutical and biotech industry, has signed a multi-year contract with Elsevier, which will provide unlimited Reaxys access to all Pharmaron researchers.

29 Aug 2011

EAS/ESC develops new dyslipidaemias guidelines

Clinicians should aim for comprehensive lipid control using lifestyle as a first step and tailoring treatment to patients. Lifestyle interventions, including stopping smoking, improving diet, exercising sufficiently and moderate alcohol consumption, should be the crucial first step for managing lipids in all patients.

29 Aug 2011